A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
The purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping...
Saved in:
Main Author: | |
---|---|
Format: | article |
Language: | EN |
Published: |
University of Minnesota Libraries Publishing
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/d7b83b07b71f43c58222455a5e18945b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|